Gyre Therapeutics

Gyre Therapeutics is a commercial-stage biopharmaceutical company developing small-molecule therapies for organ fibrosis and inflammatory disease, operating in both the United States and China. Through its majority-owned subsidiary Gyre Pharmaceuticals it markets ETUARY (pirfenidone capsule), the first approved treatment for idiopathic pulmonary fibrosis in China, and is advancing F351 (hydronidone) — a structurally modified pirfenidone derivative targeting TGF-beta1 signalling — for chronic hepatitis B-associated liver fibrosis in China, where the NDA was accepted with priority review in 2026, and for MASH-associated liver fibrosis in the United States. A May 2026 all-stock acquisition of Cullgen added a targeted protein degrader and degrader-antibody conjugate discovery platform. The company is headquartered in San Diego and majority-owned by GNI USA.